Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2010, Article ID 417646, 7 pages
http://dx.doi.org/10.1155/2010/417646
Review Article

Peroxisome Proliferator-Activated Receptors Protect against Apoptosis via 14-3-3

Institute of Cellular and System Medicine, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 350, Taiwan

Received 26 May 2010; Accepted 14 July 2010

Academic Editor: Tianxin Yang

Copyright © 2010 Kenneth K. Wu. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Robinson and D. J. Grieve, “Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease,” Pharmacology and Therapeutics, vol. 122, no. 3, pp. 246–263, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Bishop-Bailey and J. Bystrom, “Emerging roles of peroxisome proliferator-activated receptor-β/δ in inflammation,” Pharmacology and Therapeutics, vol. 124, no. 2, pp. 141–150, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Kersten, B. Desvergne, and W. Wahli, “Roles of PPARS in health and disease,” Nature, vol. 405, no. 6785, pp. 421–424, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. J.-Y. Liou, S. Lee, D. Ghelani, N. Matijevic-Aleksic, and K. K. Wu, “Protection of endothelial survival by peroxisome proliferator-activated receptor-δ mediated 14-3-3 upregulation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 7, pp. 1481–1487, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. K. K. Wu and J.-Y. Liou, “Cellular and molecular biology of prostacyclin synthase,” Biochemical and Biophysical Research Communications, vol. 338, no. 1, pp. 45–52, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. J. S. Pober and R. S. Cotran, “Cytokines and endothelial cell biology,” Physiological Reviews, vol. 70, no. 2, pp. 427–451, 1990. View at Google Scholar · View at Scopus
  7. S. Bunting, S. Moncada, and J. R. Vane, “The prostacyclin-thromboxane A2 balance: pathophysiological and therapeutic implications,” British Medical Bulletin, vol. 39, no. 3, pp. 271–276, 1983. View at Google Scholar · View at Scopus
  8. J. A. Oates, G. A. FitzGerald, R. A. Branch, E. K. Jackson, H. R. Knapp, and L. J. Roberts II, “Clinical implications of prostaglandin and thromboxane A2 formation (first of two parts),” New England Journal of Medicine, vol. 319, no. 11, pp. 689–698, 1988. View at Google Scholar · View at Scopus
  9. A. N. Hata and R. M. Breyer, “Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation,” Pharmacology and Therapeutics, vol. 103, no. 2, pp. 147–166, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. S. R. Adderley and D. J. Fitzgerald, “Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediate induction of cyclooxygenase-2,” Journal of Biological Chemistry, vol. 274, no. 8, pp. 5038–5046, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. C.-M. Hao, M. Kömhoff, Y. Guan, R. Redha, and M. D. Breyer, “Selective targeting of cyclooxygenase-2 reveals its role in renal medullary interstitial cell survival,” American Journal of Physiology—Renal Physiology, vol. 277, no. 3, part 2, pp. F352–F359, 1999. View at Google Scholar · View at Scopus
  12. R. G. Pozner, S. Negrotto, L. P. D'Atri et al., “Prostacyclin prevents nitric oxide-induced megakaryocyte apoptosis,” British Journal of Pharmacology, vol. 145, no. 3, pp. 283–292, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. B. M. Forman, J. Chen, and R. M. Evans, “Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4312–4317, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. C.-M. Hao, R. Redha, J. Morrow, and M. D. Breyer, “Peroxisome proliferator-activated receptor δ activation promotes cell survival following hypertonic stress,” Journal of Biological Chemistry, vol. 277, no. 24, pp. 21341–21345, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Di-Po, N. S. Tan, L. Michalik, W. Wahli, and B. Desvergne, “Antiapoptotic role of PPARβ in keratinocytes via transcriptional control of the Akt1 signaling pathway,” Molecular Cell, vol. 10, no. 4, pp. 721–733, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Pesant, S. Sueur, P. Dutartre et al., “Peroxisome proliferator-activated receptor δ (PPARδ) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis,” Cardiovascular Research, vol. 69, no. 2, pp. 440–449, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Wan, L. Jiang, Q. Lü, L. Ke, X. Li, and N. Tong, “Activation of PPARδ up-regulates fatty acid oxidation and energy uncoupling genes of mitochondria and reduces palmitate-induced apoptosis in pancreatic β-cells,” Biochemical and Biophysical Research Communications, vol. 391, no. 3, pp. 1567–1572, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. H. J. Kim, M. Y. Kim, H. Jin et al., “Peroxisome proliferator-activated receptor δ regulates extracellular matrix and apoptosis of vascular smooth muscle cells through the activation of transforming growth factor-β1/Smad3,” Circulation Research, vol. 105, no. 1, pp. 16–24, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Lin, T.-N. Lin, W.-M. Cheung et al., “Cyclooxygenase-1 and bicistronic cyclooxygenase-1/ prostacyclin synthase gene transfer protect against ischemic cerebral infarction,” Circulation, vol. 105, no. 16, pp. 1962–1969, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Fu, R. R. Subramanian, and S. C. Masters, “14-3-3 Proteins: structure, function, and regulation,” Annual Review of Pharmacology and Toxicology, vol. 40, pp. 617–647, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. D. K. Morrison, “The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development,” Trends in Cell Biology, vol. 19, no. 1, pp. 16–23, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. J.-Y. Liou, N. Matijevic-Aleksic, S. Lee, and K. K. Wu, “Prostacyclin inhibits endothelial cell XIAP ubiquitination and degradation,” Journal of Cellular Physiology, vol. 212, no. 3, pp. 840–848, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. S. J. Shiff, L. Qiao, L.-L. Tsai, and B. Rigas, “Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells,” Journal of Clinical Investigation, vol. 96, no. 1, pp. 491–503, 1995. View at Google Scholar · View at Scopus
  24. R. N. DuBois, S. B. Abramson, L. Crofford et al., “Cyclooxygenase in biology and disease,” FASEB Journal, vol. 12, no. 12, pp. 1063–1073, 1998. View at Google Scholar · View at Scopus
  25. G. A. Piazza, D. S. Alberts, L. J. Hixson et al., “Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels,” Cancer Research, vol. 57, no. 14, pp. 2909–2915, 1997. View at Google Scholar · View at Scopus
  26. R. A. Gupta, J. Tan, W. F. Krause et al., “Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 24, pp. 13275–13280, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. R. A. Gupta, D. Wang, S. Katkuri, H. Wang, S. K. Dey, and R. N. DuBois, “Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth,” Nature Medicine, vol. 10, no. 3, pp. 245–247, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. T.-C. He, T. A. Chan, B. Vogelstein, and K. W. Kinzler, “PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs,” Cell, vol. 99, no. 3, pp. 335–345, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. J.-Y. Liou, D. Ghelani, S. Yeh, and K. K. Wu, “Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3ε,” Cancer Research, vol. 67, no. 7, pp. 3185–3191, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. J.-Y. Liou, C.-C. Wu, B.-R. Chen, L. B. Yen, and K. K. Wu, “Nonsteroidal anti-inflammatory drugs induced endothelial apoptosis by perturbing peroxisome proliferator-activated receptor-δ transcriptional pathway,” Molecular Pharmacology, vol. 74, no. 5, pp. 1399–1406, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. T.-C. Ho, S.-L. Chen, Y.-C. Yang, C.-L. Liao, H.-C. Cheng, and Y.-P. Tsao, “PEDF induces p53-mediated apoptosis through PPAR gamma signaling in human umbilical vein endothelial cells,” Cardiovascular Research, vol. 76, no. 2, pp. 213–223, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Okura, M. Nakamura, Y. Takata, S. Watanabe, Y. Kitami, and K. Hiwada, “Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells,” European Journal of Pharmacology, vol. 407, no. 3, pp. 227–235, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Kilter, M. Werner, C. Roggia et al., “The PPAR-γ agonist rosiglitazone facilitates Akt rephosphorylation and inhibits apoptosis in cardiomyocytes during hypoxia/reoxygenation,” Diabetes, Obesity and Metabolism, vol. 11, no. 11, pp. 1060–1067, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. C.-Y. Lin, T. Gurlo, L. Haataja, W. A. Hsueh, and P. C. Butler, “Activation of peroxisome proliferator-activated receptor-γ by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3′-kinase-dependent pathway,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 12, pp. 6678–6686, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. J.-S. Wu, W.-M. Cheung, Y.-S. Tsai et al., “Ligand-activated peroxisome proliferator-activated receptor-γ protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3ε upregulation,” Circulation, vol. 119, no. 8, pp. 1124–1134, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Hinz, K. Brune, and A. Pahl, “15-Deoxy- Δ12,14-prostaglandin J2 inhibits the expression of proinflammatory genes in human blood monocytes via a PPAR-γ-independent mechanism,” Biochemical and Biophysical Research Communications, vol. 302, no. 2, pp. 415–420, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Lynn Wang, K. A. Frauwirth, S. M. Rangwala, M. A. Lazar, and C. B. Thompson, “Thiazolidinedione activation of peroxisome proliferator-activated receptor γ can enhance mitochondrial potential and promote cell survival,” Journal of Biological Chemistry, vol. 277, no. 35, pp. 31781–31788, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. T.-N. Lin, W.-M. Cheung, J.-S. Wu et al., “15d-prostaglandin J2 protects brain from ischemia-reperfusion injury,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 3, pp. 481–487, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Fuenzalida, R. Quintanilla, P. Ramos et al., “Peroxisome proliferator-activated receptor γ up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis,” Journal of Biological Chemistry, vol. 282, no. 51, pp. 37006–37015, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. J.-S. Wu, T.-N. Lin, and K. K. Wu, “Rosiglitazone and PPAR-γ overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins,” Journal of Cellular Physiology, vol. 220, no. 1, pp. 58–71, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. O. Barbier, I. P. Torra, Y. Duguay et al., “Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 5, pp. 717–726, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Lefebvre, G. Chinetti, J.-C. Fruchart, and B. Staels, “Sorting out the roles of PPARα in energy metabolism and vascular homeostasis,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 571–580, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Delerive, K. De Bosscher, S. Besnard et al., “Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1,” Journal of Biological Chemistry, vol. 274, no. 45, pp. 32048–32054, 1999. View at Publisher · View at Google Scholar · View at Scopus
  46. B. Staels, W. Koenig, A. Habib et al., “Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators,” Nature, vol. 393, no. 6687, pp. 790–793, 1998. View at Publisher · View at Google Scholar · View at Scopus
  47. N. Marx, G. K. Sukhova, T. Collins, P. Libby, and J. Plutzky, “PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells,” Circulation, vol. 99, no. 24, pp. 3125–3131, 1999. View at Google Scholar · View at Scopus
  48. N. S. Wayman, Y. Hattori, M. C. Mcdonald et al., “Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size,” FASEB Journal, vol. 16, no. 9, pp. 1027–1040, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. I. Inoue, S.-I. Goto, T. Matsunaga et al., “The ligands/activators for peroxisome proliferator-activated receptor α (PPARα) and PPARγ increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells,” Metabolism, vol. 50, no. 1, pp. 3–11, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. M. E. Poynter and R. A. Daynes, “Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-κB signaling, and reduces inflammatory cytokine production in aging,” Journal of Biological Chemistry, vol. 273, no. 49, pp. 32833–32841, 1998. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Deplanque, P. Gelé, O. Pétrault et al., “Peroxisome proliferator-activated receptor-α activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment,” Journal of Neuroscience, vol. 23, no. 15, pp. 6264–6271, 2003. View at Google Scholar · View at Scopus
  52. H.-H. Chen, T.-W. Chen, and H. Lin, “Prostacyclin-induced peroxisome proliferator-activated receptor-α translocation attenuates NF-κB and TNF-α activation after renal ischemia-reperfusion injury,” American Journal of Physiology—Renal Physiology, vol. 297, no. 4, pp. F1109–F1118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Li, R. Bhatt, J. Megyesi, N. Gokden, S. V. Shah, and D. Portilla, “PPAR-α ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G,” American Journal of Physiology—Renal Physiology, vol. 287, no. 5, pp. F990–F998, 2004. View at Publisher · View at Google Scholar
  54. H. Lin, C.-C. Hou, C.-F. Cheng et al., “Peroxisomal proliferator-activated receptor-α protects renal tubular cells from doxorubicin-induced apoptosis,” Molecular Pharmacology, vol. 72, no. 5, pp. 1238–1245, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. H.-H. Chen, Y.-M. Sue, C.-H. Chen et al., “Peroxisome proliferator-activated receptor alpha plays a crucial role in l-carnitine anti-apoptosis effect in renal tubular cells,” Nephrology Dialysis Transplantation, vol. 24, no. 10, pp. 3042–3049, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. D. S. De Silva, R. M. Wilson, C. Hutchinson et al., “Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 296, no. 6, pp. H1983–H1993, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. Q. N. Wu, Q. Tang, Q. Xiao, P. Wu, A. Gao, and L. Li, “PPARalpha agonist prevented the apoptosis induced by glucose and fatty acid in neonatal cardiomyocytes,” Journal of Endocrinological Investigation. In press.
  58. M. O. Hengartner, “The biochemistry of apoptosis,” Nature, vol. 407, no. 6805, pp. 770–776, 2000. View at Publisher · View at Google Scholar · View at Scopus
  59. S. R. Datta, A. Katsov, L. Hu et al., “14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation,” Molecular Cell, vol. 6, no. 1, pp. 41–51, 2000. View at Google Scholar · View at Scopus
  60. J. Zha, H. Harada, E. Yang, J. Jockel, and S. J. Korsmeyer, “Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L),” Cell, vol. 87, no. 4, pp. 619–628, 1996. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Nomura, S. Shimizu, T. Sugiyama et al., “14-3-3 Interacts directly with and negatively regulates pro-apoptotic Bax,” Journal of Biological Chemistry, vol. 278, no. 3, pp. 2058–2065, 2003. View at Publisher · View at Google Scholar · View at Scopus
  62. J. K. Han, H. S. Lee, H. M. Yang et al., “Peroxisome proliferator-activated receptor-d agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway,” Circulation, vol. 118, no. 10, pp. 1021–1033, 2008. View at Publisher · View at Google Scholar · View at Scopus